Zymeworks updates guidance: Zymeworks stock sits 16.37 percent below its high

Published on 10/06/2026 at 02:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 2026 revenue range is USD 278 million to USD 292 million. Jefferies keeps a USD 50.00 target for Zymeworks stock on September 29, 2026.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks (ISIN US98985Y1082) updated its 2026 revenue guidance to USD 278 million-USD 292 million on September 28, 2026, while its latest Nasdaq quote stood 16.37 percent below the 52-week high. The guidance followed completion of the Theravance Biopharma acquisition and adds a commercial cash-flow angle to the biotechnology company.

Revenue range expands after deal

According to Zymeworks on September 28, 2026, the company expects 2026 adjusted EBITDA of USD 114 million-USD 128 million alongside the revenue range. Both figures are guidance measures, not reported results, and exclude the impact of future transactions.

The acquisition brings YUPELRI into the portfolio. In the first half of 2026, YUPELRI sales reached USD 133.1 million and produced USD 38.4 million in collaboration revenue for Theravance Biopharma, according to Zymeworks. Hospital sales grew 25.00 percent in the second quarter of 2026, giving the transaction a measurable operating driver.

Buyback offsets part of financing

Zymeworks financed the transaction with a USD 350 million non-recourse note and used USD 217.5 million of existing cash resources for the remaining purchase price, according to Zymeworks. The company had used USD 49.3 million of its USD 125.0 million 2026 repurchase authorization by September 28, 2026, buying 1,971,454 shares at an average price of USD 25.04.

Analyst expectations remain higher than the current market quote. Markets Insider reported on September 29, 2026, that Jefferies maintained a Buy rating and a USD 50.00 price target, while Citi maintained a USD 39.00 target.

Nasdaq quote below yearly high

The latest primary-market quote was USD 26.21 on Nasdaq on October 5, 2026 at 4:00 p.m. ET. Against the USD 31.34 52-week high, the quote was 16.37 percent lower, while the 52-week range was USD 16.00 to USD 31.34.

Lang & Schwarz listed a prior close of EUR 23.35 for October 2, 2026. The next quarterly reporting date is November 10, 2026, according to The Wall Street Journal.